Mary K. Olson

772 total citations
35 papers, 520 citations indexed

About

Mary K. Olson is a scholar working on Economics and Econometrics, Pharmacology and Management of Technology and Innovation. According to data from OpenAlex, Mary K. Olson has authored 35 papers receiving a total of 520 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Economics and Econometrics, 12 papers in Pharmacology and 9 papers in Management of Technology and Innovation. Recurrent topics in Mary K. Olson's work include Pharmaceutical Economics and Policy (20 papers), Pharmaceutical industry and healthcare (12 papers) and Intellectual Property and Patents (9 papers). Mary K. Olson is often cited by papers focused on Pharmaceutical Economics and Policy (20 papers), Pharmaceutical industry and healthcare (12 papers) and Intellectual Property and Patents (9 papers). Mary K. Olson collaborates with scholars based in United States, China and Taiwan. Mary K. Olson's co-authors include M. Kathryn Stewart, Holly C. Felix, Glen P. Mays, Christina Reaves, Ann M. Cheney, Tiffany Haynes, Geoffrey M. Curran, J. Greer Sullivan, Christine E. Sheffer and Greer Sullivan and has published in prestigious journals such as Journal of Autism and Developmental Disorders, International Journal of Environmental Research and Public Health and Health Affairs.

In The Last Decade

Mary K. Olson

33 papers receiving 478 citations

Peers

Mary K. Olson
John W. Kenagy United States
Ellen R. Shaffer United States
Jonathan D. Ketcham United States
Lise Rochaix France
Manthan D Janodia India
Darren E. Ƶinner United States
Ethan M.J. Lieber United States
Jaeun Shin South Korea
A. Finkelstein Canada
Stéphane Jacobzone France
John W. Kenagy United States
Mary K. Olson
Citations per year, relative to Mary K. Olson Mary K. Olson (= 1×) peers John W. Kenagy

Countries citing papers authored by Mary K. Olson

Since Specialization
Citations

This map shows the geographic impact of Mary K. Olson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary K. Olson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary K. Olson more than expected).

Fields of papers citing papers by Mary K. Olson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary K. Olson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary K. Olson. The network helps show where Mary K. Olson may publish in the future.

Co-authorship network of co-authors of Mary K. Olson

This figure shows the co-authorship network connecting the top 25 collaborators of Mary K. Olson. A scholar is included among the top collaborators of Mary K. Olson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary K. Olson. Mary K. Olson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Walpole, Hugh, Jennifer E. Sutton, & Mary K. Olson. (2025). Are we safe yet? Experimental analysis of emergency post-alert messages. International Journal of Disaster Risk Reduction. 128. 105753–105753.
2.
Olson, Mary K., et al.. (2018). Examining Firm Responses to R&D Policy: An Analysis of Pediatric Exclusivity. SSRN Electronic Journal. 1 indexed citations
3.
Stewart, M. Kathryn, et al.. (2015). Community Engagement in Health-Related Research: A Case Study of a Community-Linked Research Infrastructure, Jefferson County, Arkansas, 2011–2013. Preventing Chronic Disease. 12. E115–E115. 11 indexed citations
4.
Olson, Mary K., et al.. (2015). Engaging Underrepresented Minorities in Research: Our Vision for a “Research-Friendly Community”. Progress in community health partnerships. 9(4). 595–598. 5 indexed citations
5.
Olson, Mary K.. (2013). Eliminating the U.S. Drug Lag: Implications for Drug Safety. SSRN Electronic Journal. 1 indexed citations
6.
Olson, Mary K.. (2013). Eliminating the U.S. drug lag: Implications for drug safety. Journal of Risk and Uncertainty. 47(1). 1–30. 9 indexed citations
7.
Felix, Holly C., et al.. (2011). Medicaid Savings Resulted When Community Health Workers Matched Those With Needs To Home And Community Care. Health Affairs. 30(7). 1366–1374. 65 indexed citations
8.
Olson, Mary K.. (2009). PDUFA and Initial U.S. Drug Launches. 15(2). 393–416. 1 indexed citations
9.
Olson, Mary K.. (2008). The Risk We Bear: The Effects of Review Speed and Industry User Fees on New Drug Safety. SSRN Electronic Journal. 1 indexed citations
10.
Olson, Mary K.. (2007). The risk we bear: The effects of review speed and industry user fees on new drug safety. Journal of Health Economics. 27(2). 175–200. 55 indexed citations
11.
Felix, Holly C., et al.. (2007). Linking Residents to Long-Term Care Services: First-Year Findings from the Community Connector Program Evaluation. Progress in community health partnerships. 1(4). 311–319. 6 indexed citations
12.
Olson, Mary K.. (2005). Managed Care and Monopoly Power. Journal of Health Politics Policy and Law. 30(3). 530–534. 1 indexed citations
13.
Olson, Mary K.. (2004). Are Novel Drugs More Risky for Patients than Less Novel Drugs. SSRN Electronic Journal. 2 indexed citations
14.
Olson, Mary K.. (2004). Are novel drugs more risky for patients than less novel drugs?. Journal of Health Economics. 23(6). 1135–1158. 54 indexed citations
15.
Olson, Mary K.. (2003). Pharmaceutical Policy Change and the Safety of New Drugs. SSRN Electronic Journal.
16.
Olson, Mary K.. (2003). Managing Delegation in the FDA: Reducing Delay in New-Drug Review. Project Muse (Johns Hopkins University). 1 indexed citations
17.
Olson, Mary K.. (1999). Agency Rulemaking, Political Influences, Regulation, and Industry Compliance. SSRN Electronic Journal. 2 indexed citations
18.
Olson, Mary K.. (1998). Regulatory Agency Discretion Among Competing Industries: Inside the Fda. SSRN Electronic Journal. 4 indexed citations
19.
Olson, Mary K.. (1997). Firm Characteristics and the Speed of FDA Approval. Journal of Economics & Management Strategy. 6(1). 377–401. 40 indexed citations
20.
Olson, Mary K.. (1995). Regulatory Agency Discretion among Competing Industries: Inside the FDA. The Journal of Law Economics and Organization. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John W. Kenagy Breakdown of academic impact, for papers by Ellen R. Shaffer Breakdown of academic impact, for papers by Jonathan D. Ketcham Breakdown of academic impact, for papers by Lise Rochaix Breakdown of academic impact, for papers by Manthan D Janodia Breakdown of academic impact, for papers by Darren E. Ƶinner Breakdown of academic impact, for papers by Ethan M.J. Lieber Breakdown of academic impact, for papers by Jaeun Shin Breakdown of academic impact, for papers by A. Finkelstein Breakdown of academic impact, for papers by Stéphane Jacobzone
Rankless by CCL
2026